Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC

May 31st 2024

Viktor Grünwald, MD, PhD, on patterns of progression and subsequent therapy for patients with advanced RCC treated during the phase 3 CLEAR trial.

Revisit Every OncLive On Air Episode From May 2024

May 30th 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

Dr Braun on the Evolution of Immunotherapy Combinations in RCC

May 29th 2024

David A. Braun, MD, PhD, discusses considerations with immunotherapy-based regimens in patients with renal cell carcinoma.

Nivolumab/Cabozantinib Combination Displays Activity in Non-Clear Cell RCC

May 29th 2024

Treatment with nivolumab plus cabozantinib yielded responses in patients with non-clear cell renal cell carcinoma.

Retrospective Data Shed Light on Prognostic Value of PD-L1 Expression in Metastatic Papillary RCC

May 27th 2024

Positive PD-L1 expression was associated with worse survival in metastatic papillary renal cell carcinoma.

Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma

May 23rd 2024

Sumanta Kumar Pal, MD, FASCO, discusses key biomarker analyses in renal cell carcinoma that will be presented at the 2024 ASCO Annual Meeting.

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

May 23rd 2024

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.

Addressing Research Into the Association Between Tumor Mutations and Responses in RCC

May 21st 2024

Eliezer Van Allen, MD, discusses immuno-oncology in relation to precision cancer medicine.

TIBs Linked With Poor Outcomes With Anti–PD-1 Therapy Plus Axitinib in Metastatic ccRCC

May 21st 2024

Tumor-infiltrating B lymphocytes were associated with worse outcomes in patients with metastatic ccRCC treated with axitinib plus anti–PD-1 therapy.

FDA Updates PDUFA Date of BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors

May 21st 2024

The FDA has updated the PDUFA target action date for the BLA for subcutaneous nivolumab in advanced or metastatic solid tumors.

Dr Lim on Treatment With FOLFIRINOX vs NALIRIFOX in Metastatic Pancreatic Cancer

May 16th 2024

Kian-Huat Lim, MD, PhD, discusses factors influencing the choice between treatment with FOLFIRINOX or NALIRIFOX for metastatic pancreatic cancer.

Dr Garmezy on Future Therapeutic Prospects for RCC

May 15th 2024

Meta: Benjamin Garmezy, MD discusses future therapeutic prospects for patients with variant renal cell carcinoma (RCC)

OncLive’s April Roundup of Key FDA Decisions in Oncology

May 14th 2024

In case you missed it, below is your guide to the important regulatory approvals made by the FDA in April 2024.

Salvage Nivolumab/Ipilimumab Following Nivolumab Affords Treatment-Free Survival in RCC

May 11th 2024

Salvage treatment with nivolumab plus ipilimumab following progression on nivolumab alone led to significant treatment-free survival in advanced ccRCC.

Retrospective Data Show Metastasectomy Plus Nephrectomy Improves Survival in Non–ccRCC

May 10th 2024

A retrospective analysis showed that metastasectomy plus radical nephrectomy could improve survival in patients with metastatic non–clear cell RCC.

Dr Beckermann on Targeting TREM2 in the Treatment of ccRCC

May 7th 2024

Kathryn Beckermann, MD, PhD, discusses ongoing studies investigating the role of TREM2 in the treatment of patients with clear cell renal cell carcinoma.

Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC

May 6th 2024

Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.

FDA Accepts BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors

May 6th 2024

The FDA has accepted a biologics license application for subcutaneous nivolumab for adult patients eligible for approved solid tumor nivolumab indications.

Dr Wang on the Role of Active Surveillance in Patients With Renal Masses

May 4th 2024

Katherine Wang, MD, discusses the role of active surveillance for patients with renal masses and the ongoing MUSIC-KIDNEY project in Michigan.

Dr Merchán on the Future Treatment of Advanced RCC

May 3rd 2024

Jaime R. Merchán, MD, discusses the future treatment of patients with advanced renal cell carcinoma.